Skip to main content

Table 2 Clinical trials using nanoparticles with melanoma patients

From: Magnetic nanoparticles in theranostics of malignant melanoma

Clinical trial no. Phase Patients Study design Status Purpose Refs
NCT00626405 II Unresectable stage IV melanoma Bevacizumab + Temozolomide vs Bevacizumab + paclitaxel albumin-stabilized nanoparticle formulation + carboplatin Completed Treatment [100]
NCT00081042 II Unresectable stage IV melanoma Paclitaxel albumin-stabilized nanoparticle formulation; previously chemotherapy vs chemotherapy-naive Completed Treatment [101]
NCT00738361 II Unresectable metastatic uveal melanoma Paclitaxel albumin-stabilized nanoparticle formulation; single group Completed Treatment  
NCT00404235 II Unresectable stage IV melanoma Paclitaxel albumin-stabilized nanoparticle formulation; chemotherapy-naïve; single group Completed Treatment [100]
NCT02158520 II Unresectable stage IV melanoma Bevacizumab + paclitaxel albumin-stabilized nanoparticle formulation vs ipilimumab Completed Treatment [103]
NCT01300533 I Advanced or metastatic cancer including melanoma BIND-014: targeted docetaxel polymeric nanoparticle; single group Completed Treatment [104]
NCT02668536 I Melanoma and UV ray damaged skin Standard sunscreen vs sunscreen based on bioadhesive nanoparticles Completed Prevention [105]
NCT04899908 II Cancer with brain metastasis including melanoma Stereotactic radiation with vs without AGuIX gadolinium-based nanoparticles Recruiting Treatment  
NCT03739931 I Advanced malignancies including melanoma Lipid nanoparticle encapsulating mRNAs with vs without durvalumab Recruiting Treatment  
NCT02106598 II Head and neck melanoma Silica nanoparticles with fluorescent cRGDY-PEG-Cy5.5-C dots for real-time image-guided intraoperative mapping of nodal metastases Recruiting Diagnostic  
  1. Completed and recruiting clinical studies currently listed in the NIH database of the U.S. National Library of Medicine(https://clinicaltrials.gov)